



TCR² Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Cambridge, MA, August 8, 2017 – TCR² Therapeutics Inc. announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 12:45PM Eastern Time. The event will be held in New York, NY at Le Parker Meridien.

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a \$44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

###